Company / Cash & Equivalents
Edwards Lifesciences Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.9B
FY2025
5-year range
$769.0M / $3.0B
FY2021-FY2025
Trend
-3.5%
vs FY2024
Sector context
#16 of 148
Health Care
What the data says
Edwards Lifesciences's cash & equivalents of $2.9B is higher than 89% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $714M in FY2018 to $3.0B in FY2024.
Based on SEC 10-K filings.
$2.9B in FY2025 with a 5-year CAGR of +19.9%. Top quartile in the Health Care sector.
Improved from $1.1B to $2.9B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +56.3%
- 5-Year CAGR
- +19.9%
- 10-Year CAGR
- -
Sector benchmark
+149.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +19.9%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 3.5% year-over-year.
- Ranks #16 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.9B | -3.5% |
| FY2024 | $3.0B | +166.2% |
| FY2023 | $1.1B | +48.8% |
| FY2022 | $769.0M | -10.9% |
| FY2021 | $862.8M | -27.1% |
| FY2020 | $1.2B | +0.3% |
| FY2019 | $1.2B | +65.1% |
| FY2018 | $714.1M | -12.7% |
| FY2017 | $818.3M | -12.0% |
| FY2016 | $930.1M | +29.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026